Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - prasugrel, quantity: 5 mg - tablet, film coated - excipient ingredients: sucrose stearate; microcrystalline cellulose; lactose monohydrate; crospovidone; croscarmellose sodium; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow - prasugrel, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

golden state medical supply, inc. - prasugrel hydrochloride (unii: g89jq59i13) (prasugrel - unii:34k66tbt99) - prasugrel tablet is indicated to reduce the rate of thrombotic cardiovascular (cv) events (including stent thrombosis) in patients with acute coronary syndrome (acs) who are to be managed with percutaneous coronary intervention (pci) as follows: - patients with unstable angina (ua) or non-st-elevation myocardial infarction (nstemi). - patients with st-elevation myocardial infarction (stemi) when managed with primary or delayed pci. prasugrel tablet has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (mi), or nonfatal stroke compared to clopidogrel. the difference between treatments was driven predominantly by mi, with no difference on strokes and little difference on cv death [see clinical studies ( 14)] . prasugrel tablet is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see warnings and precautions (5.1) a

Израел - Енглески - Ministry of Health

trima israel pharmaceutical products maabarot ltd - prasugrel - film coated tablets - prasugrel 10 mg - prasugrel - prasugrel - trima 10 mg, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi] undergoing primary or delayed percutaneous coronary intervention (pci). the increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had tia/cva in the past and in those above the age of 75 or weight below 60 kg.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

eli lilly and company - prasugrel hydrochloride (unii: g89jq59i13) (prasugrel - unii:34k66tbt99) - prasugrel 5 mg - effient® is indicated to reduce the rate of thrombotic cardiovascular (cv) events (including stent thrombosis) in patients with acute coronary syndrome (acs) who are to be managed with percutaneous coronary intervention (pci) as follows: - patients with unstable angina (ua) or non-st-elevation myocardial infarction (nstemi). - patients with st-elevation myocardial infarction (stemi) when managed with primary or delayed pci. effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (mi), or nonfatal stroke compared to clopidogrel. the difference between treatments was driven predominantly by mi, with no difference on strokes and little difference on cv death [see clinical studies (14)] . effient is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see warnings and precautions (5.1) and adverse reactions (6.1)] . effient is contraindicated in patients with a history of prior transient isc

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - prasugrel, quantity: 5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; crospovidone; sucrose stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow - prasugrel, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - prasugrel, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; sucrose stearate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - prasugrel, co-administered with aspirin, is indicated for the prevention of atherothrombotic events (myocardial infarction, stroke and cardiovascular death) in patients with acute coronary syndromes (moderate to high risk unstable angina (ua), non st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi)) who are to undergo percutaneous coronary intervention (pci).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - prasugrel -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - prasugrel -

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - prasugrel hydrochloride (unii: g89jq59i13) (prasugrel - unii:34k66tbt99) - prasugrel tablets are indicated to reduce the rate of thrombotic cv events (including stent thrombosis) in patients with acute coronary syndrome (acs) who are to be managed with percutaneous coronary intervention (pci) as follows: - patients with unstable angina (ua) or non-st-elevation myocardial infarction (nstemi). - patients with st-elevation myocardial infarction (stemi) when managed with primary or delayed pci. prasugrel tablets has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (mi), or nonfatal stroke compared to clopidogrel. the difference between treatments was driven predominantly by mi, with no difference on strokes and little difference on cv death [see clinical studies (14)]. prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage (ich) [see warnings and precautions (5.1) and adverse reactions (6.1)]. prasugrel is contraindicated in patients with a history of

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

american health packaging - prasugrel hydrochloride (unii: g89jq59i13) (prasugrel - unii:34k66tbt99) - prasugrel tablets are indicated to reduce the rate of thrombotic cv events (including stent thrombosis) in patients with acute coronary syndrome (acs) who are to be managed with percutaneous coronary intervention (pci) as follows: - patients with unstable angina (ua) or non-st-elevation myocardial infarction (nstemi). - patients with st-elevation myocardial infarction (stemi) when managed with primary or delayed pci. prasugrel tablets have been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (mi), or nonfatal stroke compared to clopidogrel. the difference between treatments was driven predominantly by mi, with no difference on strokes and little difference on cv death [see clinical studies (14)]. prasugrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage (ich) [see warnings and precautions (5.1) and